18,032 Shares in Hologic, Inc. (NASDAQ:HOLX) Purchased by FCF Advisors LLC

FCF Advisors LLC acquired a new position in Hologic, Inc. (NASDAQ:HOLX) during the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 18,032 shares of the medical equipment provider’s stock, valued at approximately $1,469,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Innealta Capital LLC purchased a new position in Hologic in the 2nd quarter valued at about $25,000. iA Global Asset Management Inc. purchased a new position in Hologic in the 1st quarter valued at about $37,000. Sunbelt Securities Inc. purchased a new position in Hologic in the 2nd quarter valued at about $37,000. Cranbrook Wealth Management LLC purchased a new position in Hologic in the 2nd quarter valued at about $47,000. Finally, Mather Group LLC. purchased a new position in Hologic in the 1st quarter valued at about $48,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on HOLX. Needham & Company LLC restated a “buy” rating and issued a $90.00 target price on shares of Hologic in a report on Tuesday, September 17th. Stephens restated an “overweight” rating and issued a $92.00 target price on shares of Hologic in a report on Tuesday, July 30th. Mizuho increased their price objective on shares of Hologic from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Friday. JPMorgan Chase & Co. increased their price objective on shares of Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, July 30th. Finally, StockNews.com lowered shares of Hologic from a “strong-buy” rating to a “buy” rating in a report on Friday, September 27th. Five research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, Hologic presently has an average rating of “Moderate Buy” and a consensus price target of $87.50.

Insider Activity

In other news, CEO Stephen P. Macmillan sold 3,672 shares of the firm’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total transaction of $294,237.36. Following the transaction, the chief executive officer now directly owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the transaction, the insider now directly owns 3,735 shares of the company’s stock, valued at $310,415.85. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the transaction, the chief executive officer now directly owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 18,280 shares of company stock valued at $1,469,973. Company insiders own 1.75% of the company’s stock.

Hologic Stock Performance

HOLX stock traded up $0.36 during mid-day trading on Tuesday, reaching $80.24. The company had a trading volume of 232,977 shares, compared to its average volume of 1,591,744. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $18.73 billion, a P/E ratio of 40.76, a P/E/G ratio of 2.58 and a beta of 0.98. Hologic, Inc. has a one year low of $64.02 and a one year high of $84.67. The stock’s 50-day simple moving average is $81.28 and its two-hundred day simple moving average is $77.48.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The company’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period last year, the company earned $0.93 earnings per share. Research analysts anticipate that Hologic, Inc. will post 4.09 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.